SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    Prescription EPA and plaque: EVAPORATE did not test ordinary fish-oil capsules

    EVAPORATE reported regression of a specific coronary plaque measure with icosapent ethyl added to statins. Its prescription formulation and imaging endpoint limit transfer to generic fish-oil claims.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    A named EPA medicine was added to statin treatment

    The trial enrolled 80 patients with coronary atherosclerosis and persistently elevated triglycerides who were taking statins. They received icosapent ethyl, a purified EPA ethyl ester, or placebo for 18 months. [1]

    The primary CT-derived low-attenuation plaque volume decreased by 17% in the active group and increased by 109% in the placebo group. Those percentages describe that plaque category, not the percentage of all arterial blockage removed. [1]

    Imaging and clinical events are different endpoints

    This trial investigated plaque characteristics rather than proving a reduction in heart attacks within its small sample. It also did not test an arbitrary over-the-counter EPA/DHA mixture. [1]

    Funding and conflicts were not fully assessed from the abstract. The result should be interpreted alongside evidence for the specific medicine and the patient’s clinical indication. It does not support replacing statins or describing all fish oil as an artery-clearing treatment. [1]

    Preserve the denominator in a percentage claim

    Imagine one imaging-defined plaque component falls by 17%. That is not the same as saying an artery becomes 17% less blocked or every plaque component shrinks.

    Evidence summary — Prescription EPA and plaque
    DetailInterpretation
    Icosapent ethylSpecific prescription preparation
    Low-attenuation plaque volumePrimary imaging endpoint
    Generic fish-oil capsulesNot tested
    Prescription EPA and plaque: EVAPORATE did not test ordinary fish-oil capsules — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PubMed
      Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.